Literature DB >> 17923632

Three-dimensional gray matter atrophy mapping in mild cognitive impairment and mild Alzheimer disease.

Liana G Apostolova1, Calen A Steiner, Gohar G Akopyan, Rebecca A Dutton, Kiralee M Hayashi, Arthur W Toga, Jeffrey L Cummings, Paul M Thompson.   

Abstract

BACKGROUND: Alzheimer disease (AD) is the most common form of dementia worldwide. Mild cognitive impairment (MCI) is the recent terminology for patients with cognitive deficiencies in the absence of functional decline. Most patients with MCI harbor the pathologic changes of AD and demonstrate transition to dementia at a rate of 10% to 15% per year. Patients with AD and MCI experience progressive brain atrophy.
OBJECTIVE: To analyze the structural magnetic resonance imaging data for 24 patients with amnestic MCI and 25 patients with mild AD using an advanced 3-dimensional cortical mapping technique.
DESIGN: Cross-sectional cohort design. Patients/
METHODS: We analyzed the structural magnetic resonance imaging data of 24 amnestic MCI (mean MMSE, 28.1; SD, 1.7) and 25 mild AD patients (all MMSE scores, >18; mean MMSE, 23.7; SD, 2.9) using an advanced 3-dimensional cortical mapping technique.
RESULTS: We observed significantly greater cortical atrophy in patients with mild AD. The entorhinal cortex, right more than left lateral temporal cortex, right parietal cortex, and bilateral precuneus showed 15% more atrophy and the remainder of the cortex primarily exhibited 10% to 15% more atrophy in patients with mild AD than in patients with amnestic MCI.
CONCLUSION: There are striking cortical differences between mild AD and the immediately preceding cognitive state of amnestic MCI. Cortical areas affected earlier in the disease process are more severely affected than those that are affected late. Our method may prove to be a reliable in vivo disease-tracking technique that can also be used for evaluating disease-modifying therapies in the future.

Entities:  

Mesh:

Year:  2007        PMID: 17923632      PMCID: PMC3197839          DOI: 10.1001/archneur.64.10.1489

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  27 in total

1.  Detection of grey matter loss in mild Alzheimer's disease with voxel based morphometry.

Authors:  G B Frisoni; C Testa; A Zorzan; F Sabattoli; A Beltramello; H Soininen; M P Laakso
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-12       Impact factor: 10.154

2.  A voxel-based morphometry study of temporal lobe gray matter reductions in Alzheimer's disease.

Authors:  Geraldo F Busatto; Griselda E J Garrido; Osvaldo P Almeida; Claudio C Castro; Cândida H P Camargo; Carla G Cid; Carlos A Buchpiguel; Sergio Furuie; Cassio M Bottino
Journal:  Neurobiol Aging       Date:  2003 Mar-Apr       Impact factor: 4.673

3.  Asymmetry of pathology in Alzheimer's disease.

Authors:  I Janota; C Q Mountjoy
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-07       Impact factor: 10.154

Review 4.  Mapping cortical change in Alzheimer's disease, brain development, and schizophrenia.

Authors:  Paul M Thompson; Kiralee M Hayashi; Elizabeth R Sowell; Nitin Gogtay; Jay N Giedd; Judith L Rapoport; Greig I de Zubicaray; Andrew L Janke; Stephen E Rose; James Semple; David M Doddrell; Yalin Wang; Theo G M van Erp; Tyrone D Cannon; Arthur W Toga
Journal:  Neuroimage       Date:  2004       Impact factor: 6.556

5.  Dynamics of gray matter loss in Alzheimer's disease.

Authors:  Paul M Thompson; Kiralee M Hayashi; Greig de Zubicaray; Andrew L Janke; Stephen E Rose; James Semple; David Herman; Michael S Hong; Stephanie S Dittmer; David M Doddrell; Arthur W Toga
Journal:  J Neurosci       Date:  2003-02-01       Impact factor: 6.167

6.  Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.

Authors:  G McKhann; D Drachman; M Folstein; R Katzman; D Price; E M Stadlan
Journal:  Neurology       Date:  1984-07       Impact factor: 9.910

7.  A comparison between the accuracy of voxel-based morphometry and hippocampal volumetry in Alzheimer's disease.

Authors:  Cristina Testa; Mikko P Laakso; Francesca Sabattoli; Roberta Rossi; Alberto Beltramello; Hilkka Soininen; Giovanni B Frisoni
Journal:  J Magn Reson Imaging       Date:  2004-03       Impact factor: 4.813

8.  Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD.

Authors:  C R Jack; M M Shiung; J L Gunter; P C O'Brien; S D Weigand; D S Knopman; B F Boeve; R J Ivnik; G E Smith; R H Cha; E G Tangalos; R C Petersen
Journal:  Neurology       Date:  2004-02-24       Impact factor: 9.910

9.  Automatic differentiation of anatomical patterns in the human brain: validation with studies of degenerative dementias.

Authors:  Catriona D Good; Rachael I Scahill; Nick C Fox; John Ashburner; Karl J Friston; Dennis Chan; William R Crum; Martin N Rossor; Richard S J Frackowiak
Journal:  Neuroimage       Date:  2002-09       Impact factor: 6.556

10.  Global and local gray matter loss in mild cognitive impairment and Alzheimer's disease.

Authors:  G B Karas; P Scheltens; S A R B Rombouts; P J Visser; R A van Schijndel; N C Fox; F Barkhof
Journal:  Neuroimage       Date:  2004-10       Impact factor: 6.556

View more
  62 in total

1.  Hippocampal, caudate, and ventricular changes in Parkinson's disease with and without dementia.

Authors:  Liana G Apostolova; Mona Beyer; Amity E Green; Kristy S Hwang; Jonathan H Morra; Yi-Yu Chou; Christina Avedissian; Dag Aarsland; Carmen C Janvin; Jan P Larsen; Jeffrey L Cummings; Paul M Thompson
Journal:  Mov Disord       Date:  2010-04-30       Impact factor: 10.338

2.  Neural correlates of impaired functional independence in early Alzheimer's disease.

Authors:  Eric D Vidoni; Robyn A Honea; Jeffrey M Burns
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

3.  Mary S. Easton Center of Alzheimer's Disease Research at UCLA: advancing the therapeutic imperative.

Authors:  Jeffrey L Cummings; John Ringman; Karen Metz
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

4.  Cortical and hippocampal atrophy in patients with autosomal dominant familial Alzheimer's disease.

Authors:  Liana G Apostolova; Kristy S Hwang; Luis D Medina; Amity E Green; Meredith N Braskie; Rebecca A Dutton; Jeffrey Lai; Daniel H Geschwind; Jeffrey L Cummings; Paul M Thompson; John M Ringman
Journal:  Dement Geriatr Cogn Disord       Date:  2011-09-23       Impact factor: 2.959

Review 5.  The clinical value of large neuroimaging data sets in Alzheimer's disease.

Authors:  Arthur W Toga
Journal:  Neuroimaging Clin N Am       Date:  2011-12-17       Impact factor: 2.264

Review 6.  Brain mapping as a tool to study neurodegeneration.

Authors:  Liana G Apostolova; Paul M Thompson
Journal:  Neurotherapeutics       Date:  2007-07       Impact factor: 7.620

7.  Tensor-based morphometry as a neuroimaging biomarker for Alzheimer's disease: an MRI study of 676 AD, MCI, and normal subjects.

Authors:  Xue Hua; Alex D Leow; Neelroop Parikshak; Suh Lee; Ming-Chang Chiang; Arthur W Toga; Clifford R Jack; Michael W Weiner; Paul M Thompson
Journal:  Neuroimage       Date:  2008-07-22       Impact factor: 6.556

8.  A method for inferring regional origins of neurodegeneration.

Authors:  Justin Torok; Pedro D Maia; Fon Powell; Sneha Pandya; Ashish Raj
Journal:  Brain       Date:  2018-03-01       Impact factor: 13.501

9.  Hippocampal and ventricular changes in Parkinson's disease mild cognitive impairment.

Authors:  Liana Apostolova; Guido Alves; Kristy S Hwang; Sona Babakchanian; Kolbjorn S Bronnick; Jan Petter Larsen; Paul M Thompson; Yi-Yu Chou; Ole B Tysnes; Hege K Vefring; Mona K Beyer
Journal:  Neurobiol Aging       Date:  2011-08-03       Impact factor: 4.673

10.  Voxel-wise co-analysis of macro- and microstructural brain alteration in mild cognitive impairment and Alzheimer's disease using anatomical and diffusion MRI.

Authors:  Valerie A Cardenas; Duygu Tosun; Linda L Chao; P Thomas Fletcher; Sarang Joshi; Michael W Weiner; Norbert Schuff
Journal:  J Neuroimaging       Date:  2013-02-19       Impact factor: 2.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.